The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Opdivo (nivolumab) on October 13, 2023. This approval specifically pertains to an efficacy supplement, indicating an expansion or refinement of the drug's demonstrated effectiveness in a new or existing patient population.

Background

Nivolumab, marketed as Opdivo, is a well-established immunotherapy drug. It functions as a programmed death-1 (PD-1) blocking antibody, a type of immune checkpoint inhibitor that helps the body's immune system recognize and attack cancer cells. Opdivo has received numerous prior approvals for treating various advanced cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, and others. Supplemental applications, like this one, are submitted by manufacturers to update or expand the existing approved uses of a drug, often by adding a new indication, a new patient population, or revising the dosing or administration based on new clinical data demonstrating efficacy.

What this means

This supplemental efficacy approval for Opdivo (nivolumab) indicates that the FDA has reviewed and accepted additional clinical data supporting the drug's effectiveness. While the specific details of the new indication, patient population, or other label changes are not specified in the initial approval notice, such supplements typically broaden the therapeutic scope of the drug. This could potentially offer new treatment options for patients in a specific cancer setting, or an improved understanding of nivolumab's benefits in an existing indication. Healthcare providers and researchers will need to consult the full FDA approval letter and updated prescribing information for precise details regarding the expanded use and any associated clinical implications.

Source

The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for Opdivo (nivolumab), identified as BLA 125554 S-121, was officially posted on October 13, 2023, on accessdata.fda.gov.